2P-0417 Statins: A double weapon in treating dyslipidaemic osteoporotic menopausal type 2 diabetics

Amara, F. Ben; Lachine, Nagwa Amr; Hassab, Amina; Melees, M.; Abdelaaty, Talaat; Youssef, Eslam; El-Shiekh, S.; Korani, Mohsen

doi:10.1016/s1567-5688(03)90559-9

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With regard to this issue, there is growing interest concerning the possible mechanism and the impact of statins on bones on either the experimental or the clinical level. In addition, the study came in accordance with Amara et al’s study which showed improvement in the BMD at the hip 50. Further studies were performed in vitro to support the potential mechanism of the beneficial effect of statins on bone metabolism.…”

Section: Discussionsupporting

confidence: 80%

“…In addition, the study came in accordance with Amara et al’s study which showed improvement in the BMD at the hip. 50 Further studies were performed in vitro to support the potential mechanism of the beneficial effect of statins on bone metabolism. The expression of genes such as BMP-2, COLLIA1, OCN (which demonstrate an anabolic effect) and depression of others like RANKL (leading to suppression of osteoclast activity), all stimulated by statins, may regulate the role of this class of drugs in bone formation.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Atorvastatin, a double weapon in osteoporosis treatment: an experimental and clinical study

El-Nabarawi¹,

Elwakd

Salem

2017

DDDT

View full text Add to dashboard Cite

ObjectiveThe aim of this study was to evaluate the effect of atorvastatin on the bone formation and resorption markers in ovariectomized rats (experimental study), and to study its effect on the bone mineral density (BMD) in postmenopausal osteoporotic women (clinical study).Materials and methodsThe study involved experimental and clinical aspects. In the experimental aspect, 42 female Wistar rats were divided into five groups: Group I (n=6; sham-operated), Group II (n=6; 1 mL of carboxymethyl cellulose [CMC] was administered orally), Group III (n=6; 20 mg/kg orally of atorvastatin was administered), Group IV (n=12; untreated ovariectomized [OVX] rats and served as a model of osteoporosis [OP]) and Group V (n=12; 20 mg/kg orally of atorvastatin was administered to ovariectomized rats). After 4 weeks, serum acid phosphatase, alkaline phosphatase, osteocalcin, total calcium and inorganic phosphorus were assessed. Then, 3 µm thickness lumbar and femur sections were examined using a light microscope to assess cortical thickness, trabecular area, numbers of osteoblasts and osteoclasts. In the clinical aspect, 85 post-menopausal osteoporotic females with recently detected hyperlipidemia participated in the study. Atorvastatin 40 mg/day, calcium carbonate 500 mg/day and vitamin D 800 international units were given to all patients for a period of 18 months. BMD was measured at the start and at the end of the study by dual-energy X-ray absorptiometry (DEXA).ResultsIn the experiment aspect, the biomarkers of bone remodeling were notably elevated in the OVX group. Administration of atorvastatin produced a significant decrease in the level of these bone metabolic markers. Atorvastatin significantly ameliorates osteoporotic changes induced by ovariectomy. In the clinical aspect, after 18 months the DEXA showed improvement in the T-score for the three measured zones; however, these changes were statistically significant only in the femoral neck area.ConclusionAtorvastatin was able to decrease the rate of bone metabolism and increase osteogenic activity. It has dual mode of action; both anabolic and antiresorptive effect on bone. This lipophilic statin member may act as a double weapon drug.

show abstract

Section: Discussionsupporting

confidence: 80%

Section: Discussionmentioning

confidence: 99%

Atorvastatin, a double weapon in osteoporosis treatment: an experimental and clinical study

El-Nabarawi¹,

Elwakd

Salem

2017

DDDT

View full text Add to dashboard Cite

show abstract

“…3) ). To the best of our knowledge, there is no published data that reported significant statin phosphate lowering potential in compromised renal failure or in the treatment of dyslipidemia, different studies showed that its effect on phosphate is non-significant as we noticed (Amara et al, 2011[ 4 ]; Perez-Castrillon et al, 2008[ 30 ]) so focus of discussion would be NER only.…”

Section: Discussionmentioning

confidence: 79%